Nasdaq · Healthcare
ANAPTYSBIO, INC (ANAB)
As-reported financials and recent SEC filings for ANAPTYSBIO, INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$234.6M
Net income
$-13.2M
Net margin
-5.6%
Diluted EPS
$-0.46
ROE
-35.6%
P/E (TTM)
—
Market cap
$1.84B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $47.9M | $-114.9M | $-164.4M | $-115.2M | $-56.8M |
| Net income | $-13.2M | $-145.2M | $-163.6M | $-128.7M | $-57.8M |
| Diluted EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →8-K2026-06-22
View on EDGAR →1442026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-16
View on EDGAR →1442026-06-15
View on EDGAR →Go deeper on ANAB
Search ANAPTYSBIO, INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.